The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer
- PMID: 18393831
- DOI: 10.2174/156652308784049363
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer
Abstract
Recombinants based on poxviruses have been used extensively as gene delivery systems to study many biological functions of foreign genes and as vaccines against many pathogens, particularly in the veterinary field. Based on safety record, efficient expression and ability to trigger specific immune responses, two of the most promising poxvirus vectors for human use are the attenuated modified vaccinia virus Ankara (MVA) and the Copenhagen derived NYVAC strains. Because of the scientific and clinical interest in these two vectors, here we review their biological characteristics, with emphasis on virus-host cell interactions, viral immunomodulators, gene expression profiling, virus distribution in animals, and application as vaccines against different pathogens and tumors.
Similar articles
-
MVA and NYVAC as vaccines against emergent infectious diseases and cancer.Curr Gene Ther. 2011 Jun;11(3):189-217. doi: 10.2174/156652311795684731. Curr Gene Ther. 2011. PMID: 21453284 Review.
-
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.Vaccine. 2007 Apr 12;25(15):2863-85. doi: 10.1016/j.vaccine.2006.09.090. Epub 2006 Oct 16. Vaccine. 2007. PMID: 17113200
-
Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.Curr Pharm Des. 2007;13(19):2015-23. doi: 10.2174/138161207781039832. Curr Pharm Des. 2007. PMID: 17627535 Review.
-
Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.Vaccine. 2012 Mar 30;30(16):2623-32. doi: 10.1016/j.vaccine.2012.02.016. Epub 2012 Feb 17. Vaccine. 2012. PMID: 22342706 Review.
-
Enhancing poxvirus vectors vaccine immunogenicity.Hum Vaccin Immunother. 2014;10(8):2235-44. doi: 10.4161/hv.28974. Hum Vaccin Immunother. 2014. PMID: 25424927 Free PMC article. Review.
Cited by
-
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.J Virol. 2011 Nov;85(21):11468-78. doi: 10.1128/JVI.05165-11. Epub 2011 Aug 24. J Virol. 2011. PMID: 21865377 Free PMC article. Clinical Trial.
-
Vaccinia virus vaccines: past, present and future.Antiviral Res. 2009 Oct;84(1):1-13. doi: 10.1016/j.antiviral.2009.06.006. Epub 2009 Jun 26. Antiviral Res. 2009. PMID: 19563829 Free PMC article. Review.
-
Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infection.J Virol. 2011 Sep;85(17):9051-9. doi: 10.1128/JVI.00619-11. Epub 2011 Jun 29. J Virol. 2011. PMID: 21715499 Free PMC article.
-
Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy.J Gen Virol. 2013 May;94(Pt 5):1121-1126. doi: 10.1099/vir.0.049700-0. Epub 2013 Jan 3. J Gen Virol. 2013. PMID: 23288427 Free PMC article.
-
Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus.Virology. 2012 Jul 5;428(2):146-55. doi: 10.1016/j.virol.2012.03.019. Epub 2012 Apr 23. Virology. 2012. PMID: 22534090 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical